Announcements Trials
Browse Landscape

Phase

Phase 2 60Phase NA 30Phase 1 30Phase 3 15Phase 1/2 15Phase EARLY_PHASE1 5Phase 2/3 5Phase 4 2

Status

Recruiting 3Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 34Thoracic 23Head & Neck 17Genitourinary 16Gynecologic 12Breast 12Other hematologic neoplasm 9Lymphoid 8Dermatologic 6Sarcoma 5Endocrine 5CNS 5Tumor-Agnostic 4NET 3Myeloid 3Plasma cell 2Other solid neoplasm 1Other 1Classical hematology 1

Conditions

Neuroendocrine Tumors 2Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Parathyroid Neoplasms 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Hyperparathyroidism, Primary 1Gastroenteropancreatic Neuroendocrine Tumors 1Adenoma, Islet Cell 1Adenocarcinoma, Follicular 1

Interventions

Everolimus 2fluorocholine 1Sodium Iodide 1Sirolimus 1Injections 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2/3 × Endocrine × 90 days × Clear all
NCT07444723 2026-05-12

Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors

National Institutes of Health Clinical Center (CC)

Phase 2/3 Recruiting
193 enrolled
EndocrineHead & Neck

Parathyroid Neoplasms, Multiple Endocrine Neoplasia Type 1, Hyperparathyroidism, Primary

NCT01398085 2026-05-07

IoN

University College, London

Phase 2/3 Active not recruiting
504 enrolled
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT01744249 2026-04-28

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Grupo Espanol de Tumores Neuroendocrinos

Phase 2/3 Completed
256 enrolled 25 charts
EndocrineNET

Neuroendocrine Tumors

NCT07165886 2026-04-24

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2/3 Recruiting
298 enrolled
EndocrineGastrointestinalNET

Gastroenteropancreatic Neuroendocrine Tumors

NCT06943755 2026-04-17

STELLAR-311

Exelixis

Phase 2/3 Recruiting
440 enrolled
EndocrineNET

Adenoma, Islet Cell, Neoplasm Metastasis, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡